Hi
There are specific definitions for those, but no need for now to dive into them. Your high level is about right and an easy way to appreciate the difference between the potential outcomes.
Secondly, just look at the below from the first cohort results of using CHM compared to
full dose comparison treatments. That's right, using our lowest dose, we achieved a 75% control rate, but only on 4 patients.. and now possibly 5 out of 7 achieved that, so 71%.
And these patients we are enrolling have a life expentency of approximately 6 months after resection, so with the standard of care treatment available they will most likely have progressed and died rapidly. To achieve disease control is to prolong this, with a partial response a longer benefit and the objective of this treatment is to achieve a complete response in as many as possible. If they even get one complete response, it will be highly price sensitive as the dosages only get higher.
And if this treatment didn't work, you wouldn't see results like this. The trouble most come across is safety at higher doses and in our case dual administration. But also what unknowns are out there that result in the treatment not working, or not working effectively i.e. what is the duration of benefit.. do the CAR-T cells stay long enough in the body/brain to achieve a partial or complete response? Are there patients that have biomarkers or particular subsets of GBM that result in a low response or non response?
All these things are hopefully going to come to light over time, but if they keep showing patients stablising or ideally improving ... that is all we can ask for. It is a long journey, but signs so far are as management say 'encouraging'. In general speak, so far so good.. but need more data over time to prove that it works with high confidence, and hopefully next year launch into a phase 2 trial which could lead to a partnership next year and/or FDA approval after that trial completes (likely around 24 months after commencement).
Patience is key!
Goodluck all
